Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Smith & Nephew SNATS Inc(SNN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SNN
09/25/2026: SNN (1-star) is currently NOT-A-BUY. Pass it for now.
Smith & Nephew SNATS Inc is an established global medical technology company focused on orthopedics, sports medicine, and advanced wound management. The company has a leading position in its specialized clinical areas and continues to invest in robotics-assisted surgical systems like CORI to drive innovation. Its primary investment story revolves around elective procedure recovery and long-term demographic trends supporting joint replacements. However, the company faces significant competitive risks from large-cap peers and is sensitive to healthcare reimbursement changes and supply chain inflation. It may suit income-oriented investors seeking stable, dividend-paying exposure to the healthcare sector, provided they monitor elective surgery volume trends.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers moderate growth potential linked to surgical innovation but faces stiff competition. |
| Momentum investor | Mixed fit | Momentum is conditional on positive trends in elective surgery volume and successful robotic platform adoption. |
| Value investor | Strong fit | The company often trades at valuations that may appeal to value-oriented investors looking for stable medical device exposure. |
| Dividend investor | Strong fit | The company maintains a consistent dividend policy suitable for income-focused portfolios. |
| Low-risk investor | Strong fit | Medical device manufacturers generally offer lower volatility compared to higher-growth tech sectors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | The stock can be sensitive to macroeconomic updates regarding hospital labor shortages and procedure volume shifts. |
| Valuation risk | Medium | Changes in interest rate environments can impact the valuation multiples assigned to stable medical device stocks. |
| Competition risk (Robotic Surgery) | High | Direct competition from large-cap players like Stryker significantly impacts market share capture for the CORI system. |
| Business quality | Strong | The company has a long history and a strong, established franchise in orthopedics and wound care. |
| Dividend income | Medium | Dividends are generally reliable but subject to changes in the company's capital allocation priorities. |
| Execution risk | Medium | Successful integration of R&D pipelines and supply chain efficiency remains critical for maintaining operating margins. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit 13.73% | Avg. Invested days 46 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 11.17B USD | Price to earnings Ratio 18.27 | 1Y Target Price 32.89 |
Price to earnings Ratio 18.27 | 1Y Target Price 32.89 | ||
Volume (30-day avg) 1.7M shares | Beta 0.68 | 52 Weeks Range 26.40 - 36.95 | Updated Date 09/25/2026 |
52 Weeks Range 26.40 - 36.95 | Updated Date 09/25/2026 | ||
Dividends yield (FY) 2.96% | Basic EPS (TTM) 1.46 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Orthopaedics | Knee and hip replacement implants and robotics-assisted surgical systems. | This is a core revenue driver tied to aging population trends and joint replacement surgeries. |
| Sports Medicine | Tools and implants for minimally invasive joint surgery. | High-growth area focusing on athletes and active patients needing repair procedures. |
| Wound Management | Advanced wound dressings and negative pressure wound therapy. | Provides stable, recurring revenue from hospital and clinical usage. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 18.27 | Forward PE 11.16 | Enterprise Value 14.56B | Price to Sales(TTM) 1.77 |
Enterprise Value 14.56B | Price to Sales(TTM) 1.77 | ||
Enterprise Value to Revenue 2.31 | Enterprise Value to EBITDA 9.26 | Shares Outstanding 418.52M | Shares Floating 2.10B |
Shares Outstanding 418.52M | Shares Floating 2.10B | ||
Percent Insiders 0.01 | Percent Institutions 11.49 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Smith & Nephew SNATS Inc
Exchange NYSE | Headquarters - | ||
IPO Launch date 1999-11-16 | CEO & Director Dr. Deepak S. Nath Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 17000 | Website https://www.smith-nephew.com |
Full time employees 17000 | Website https://www.smith-nephew.com | ||
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.